July 30, 2014—It is incumbent on the states and their Medicaid managed care contractors to ensure that drugmakers are protected against paying both a 340B discount and a Medicaid rebate on drugs provided to Medicaid managed care enrollees, a Centers for Medicare and Medicaid Services senior pharmacy official said earlier this month during a meeting of 340B stakeholders.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)